biopsies can cause several complications including breast bruising, bleeding and hematoma formation [Chou et al. 2012] . Controlling an active hemorrhage is a major challenge as a complication of biopsy procedures and therefore clinicians try to take necessary precautions to prevent this complication [Sun et al. 2014 ].
SAd-related increased bleeding risk is an emerging concern since it may contribute to the morbidity and mortality of hemorrhage in surgical settings [Tseng et al. 2013; Singh et al. 2015] . This may be particularly important when SAds are used concurrently with aspirin, nonsteroidal anti-inflammatory drugs (NSAIDs) and anticoagulants [Seitz et al. 2013 ]. There is a small, but growing literature highlighting the increased peri-operative bleeding risk with SAd use [Mahdanian et al. 2014; Singh et al. 2015] . To the best of the authors' knowledge there have only been a couple of reports examining the bleeding risk in breast surgery procedures [Basile et al. 2013; Akbulut et al. 2014] . However, no one has looked at relatively minor procedures such as breast biopsies. In this paper, we hypothesized that compared with nonbleeders, patients who bleed during their breast biopsies have higher rates of SAd exposure.
Materials and methods

Study design and setting
The current case-control study utilized retrospective data collected from 3890 patients undergoing 6300 biopsy procedures between January 2011 and October 2014 in the outpatient Breast Clinic of the McGill University Health Centre (MUHC), Montreal, Canada. Patients were only included if they were female, aged ⩾18, had complete medical records and were not using Coumadin (warfarin). Data from patients' first biopsy procedure between 2011 and 2014 were used. Ethical approval for the study was obtained from the research ethics board of the MUHC. As this was a retrospective chart review study, no consent was obtained from the patients.
Cases
In this study, cases were patients who had abnormal bleeding during their image-guided biopsy procedure. Bleeding events were reported by the board-certified radiologists who performed the biopsy procedure. The radiologists were not aware a priori of a study examining the association between SAds and bleeding. All procedures performed by radiologists were systematically documented, including any kind of complications and particularly any abnormal bleeding right at the time of the biopsy, in a checklist, with one item 'was there abnormal bleeding during the biopsy'. A survey from the radiologists of our center revealed that none of them were aware of this hypothesis that SAds may be associated with increased bleeding during surgical interventions.
Controls
Potential controls were patients undergoing biopsy procedures during the same time frame without any radiologist-reported bleeding. Using this pool of nonbleeders, up to two controls were matched with every bleeding case according to exact age and type of biopsy. With infrequently performed biopsy procedures, e.g. stereo or magnetic resonance imaging (MRI) guided vacuum biopsy, it was not always possible match two controls to each case, in which instance one control was used. This led us to have 97 patients in the case group and 137 patients in the control group.
Clinical covariates
In our study sample of female breast biopsy patients, we had matched cases and controls for important clinical covariates: age (continuous variable) and type of biopsy. Type of biopsy was categorized into three groups: ultrasound (US) guided core needle, US-guided fine needle aspiration cytology (FNAC) and stereo-or MRIguided vacuum. Other variables associated with increased bleeding risk were adjusted for in our statistical analyses. The size of the largest biopsy sample (mm) and needle caliber (gauge) were recorded as continuous variables [Al-Harethee et al. 2013] . In terms of patient medications, we looked at current SAd use, as well as pre biopsy use of medications associated with increased bleeding risk (of which only NSAIDs and aspirin had been used). It should be noted that all patients with NSAID and aspirin exposure had been strongly advised by their treating physician to stop the medication at least 1 week before the procedure. We also assessed whether biopsy pathology results were positive, since cancer can be associated with hemostatic dysfunction (either thromboembolism or hemorrhage) [Burbury, 2013] . Radiologists had used similar local anesthesia technique and agents in all patients, so these were not included amongst covariates.
Statistical analysis
Bleeders and nonbleeders were compared for type of biopsy, biopsy pathology results and use of SAds and NSAIDs using the Chi-square test. Groups were compared for age, size of biopsy and needle caliber using Student's t-test. A multivariable logistic regression was performed to determine whether SAd use was associated with bleeding, independently of age, type of biopsy, size of biopsy, pathology results, needle caliber, or NSAIDs and aspirin usage.
Results
A total of 3890 patients underwent a breast biopsy procedure. Of these, 97 (2.5%) had reports of abnormal bleeding during the procedure. These were age-and type of biopsy-matched to a control group of nonbleeders of 137 patients.
Mean age was 57.9 and 57.7 in bleeders and controls, respectively [t(232) = 0.10, p = 0.92]. All patients were female. There was a trend towards higher NSAID use amongst bleeders (12.4% versus 5.8%, χ 2 = 3.10, p = 0.078) though patients were supposed to stop those medications at least a week ahead of the breast biopsy. There was no significant difference between two groups in term of type of biopsy, size of biopsy, needle caliber and pathology results. Table 1 shows the baseline demographic and clinical characteristics of the cases and controls.
SAds were significantly associated with increased bleeding risk (10.3% versus 0.7%, Fisher's Exact p = 0.001). A total of 10 bleeding cases were exposed to SAds (7 citalopram, 3 paroxetine), whereas only one nonbleeder in the control group had used a SAd (low-dose sertraline, 25mg/day), amounting to an incidence rate of bleeding of 10/11 = 90.9% amongst SAd users in our sample. Other than SAds, none of the bleeders or nonbleeders had exposure to other types of antidepressants.
After adjusting for potentially confounding factors (age, type of biopsy, size of biopsy, pathology result, needle caliber and NSAID use), multivariate logistic regression confirmed that SAds were independently associated with elevated bleeding risk [16.2, 95% confidence interval (CI) 1.87-140.1; p = 0.01) ( Table 2) . Of note, SAds were not intercorrelated with age, type of biopsy, size of biopsy, pathology result, needle caliber and 10.3% (n = 10) 0.7% (n = 1) Fisher's Exact p = 0.001 Antiplatelet or anticoagulant medication 12.4% (n = 12) 5.8% (n = 8) χ 2 =3.10, p = 0.078 NB Patients in the 'antiplatelet/anticoagulant medication category' had only been exposed to NSAIDs or aspirin. FNAC, fine needle aspiration cytology; MRI, magnetic resonance imaging; NSAID, nonsteroidal anti-inflammatory drug; SAd, serotonergic antidepressant; SD, standard deviation; US, ultrasound.
NSAIDs use suggesting that there was no collinearity between the variables. None of the SAd users currently claimed to be taking NSAIDs or aspirin.
Discussion
To our knowledge, this is the first study to demonstrate that SAd use increases the risk of abnormal bleeding during breast biopsy procedures. Our novel use of radiological confirmation of bleeding, as opposed to using blood loss or red blood cell transfusions as a primary outcome measure, may have increased our sensitivity for detecting bleeding and facilitated finding this effect in this population. After adjusting for possible confounders, SAds were significantly associated with increased bleeding events in breast biopsy procedures (16.2, 95% CI 1.87-140.1; p = 0.01).
Most studies have found a significant association between SAd use and bleeding risk during operative procedures (OR range 1.21-4.14) [Tavakoli et al. 2012; Mahdanian et al. 2014] , with the possible exception of coronary artery bypass grafting [Kim et al. 2009; Xiong et al. 2010 et al. 2013] also found significantly increased bleeding associated with SAd use. Our finding is in line with the current theory stating that SAds may increase bleeding risk during breast interventions, but extends this to relatively minor and commonly performed interventions such as breast biopsies.
Bleeding still remains one of the most common complications of breast biopsies. The rate of bleeding in our biopsy procedures was estimated at 2.5%, which was consistent with rates of 0.76% to 7.5% in different studies [Allen et al. 2011; Zagouri et al. 2011] . Several drugs such as platelet inhibitors, vitamin K antagonists, oral anticoagulants, NSAIDs and aspirin are known to increase bleeding and therefore are routinely stopped well ahead of a biopsy procedure. In contrast, SAds are rarely, if ever, stopped because of concerns about bleeding. There are little data addressing the risks and benefits of stopping SAds and its timing. SAds are believed to increase bleeding by decreasing platelets' binding affinity due to reducing its serotonin levels [Harirchian et al. 2012] . This is important because platelet serotonin concentration decreases by more than 80% after 2 weeks of using a SAd [Hergovich et al. 2000 ]. One study by Richter and colleagues found that taking sertraline 24 hours before gastrostomy had a higher impact of bleeding (adjusted OR = 3.87, 95% CI 1.06-11.88), but not if it was used more than 48 hours before the procedure (OR = 1.0, 95% CI 0.0-11.79) [Richter et al. 2011] . Antiplatelet agents are usually withheld 7-10 days prior to biopsy procedures to allow platelet renewal [Douketis et al. 2012] .
Taking all this together, it can be inferred that SAd-related bleeding maybe less even after 2-10 days of stopping SAd. Such approaches will require testing in future clinical trials, particularly given the mental health risks of even brief SAd discontinuation [Howland, 2010] . In the meantime, clinicians should more vigilant for this possible complication in the population on SAds, particularly in patients on other agents associated with bleeding (such as NSAIDs), as they may have synergistic effects with SAds on bleeding [Douketis et al. 2012] . We should emphasize that we used a sensitive radiological assessment of bleeding, which may be a useful research probe for examining medications' potential for bleeding in moderate-sized samples (n = 100-1000), but may not be clinically important in individual breast biopsy patients. Therefore at this time, we would suggest that clinicians be aware of the potential for bleeding and not routinely discontinue SAds prior to breast biopsies.
Limitations
Our study has some limitations. First, we used retrospective data from a clinical database. As a case-control study it was more susceptible to selection bias, although we tried to minimize this by using logistic regression analyses. Our use of an age-and biopsy type-matched control group may not necessarily have controlled for confounding, but we tried to adjust for these factors in the analyses. Also, because of the low exposure rates to SAds, particularly in the control group (n = 1), we had wide 95% CIs for our effect size estimates.
Another limitation was that we did not assess depression, so that the patients suffering from it might have had a less healthy lifestyle which could possibly have played some role in their bleeding tendency. However, these possible lifestyle confounders are present in almost all studies examining SAds' relationship with bleeding [Palmsten et al. 2013 ]. Finally, bleeding was ascertained according to radiologists' clinical reports following biopsies. A quantitative estimate of bleeding or a follow-up visit to check for bruising/hematomas may have been helpful. Still, our study was the first to use subjective radiological confirmation of bleeding, an outcome measure that was likely more sensitive than some quantitative measures used (e.g. amount of blood loss), although perhaps less rigorous. Nonetheless our method was comparable with measures used in some studies in this field, in which bleeding has been defined using physician diagnostic billing codes and subjective clinical reports [Arnason et al. 200; Borzecki et al. 2011; Napenas et al. 2011; Auerbach et al. 2013; Nouraei et al. 2015] .
Conclusion
Clinicians should be aware that SAds may be associated with increased periprocedural bleeding, even in relatively minor procedures like breast biopsy. Therefore, clinicians caring for patients undergoing breast biopsies should be particularly vigilant about bleeding risk in patients using SAds. However, the decision to stop SAds before the procedure should be made with a complete discussion of the risks and benefits with other physicians involved in the care of the patient. Future research can investigate potential strategies to diminish SAd-related bleeding risk.
Clinical practice points
SAds are associated with an increased risk of bleeding during breast biopsies. From a clinical perspective, this potential risk needs to be carefully weighed against the mental health benefits of SAd use. Clinicians caring for patients undergoing breast biopsies should be particularly vigilant about bleeding risk in patients using SAds.
